Insulet Co. (NASDAQ:PODD) Receives $253.27 Consensus Target Price from Analysts

Insulet Co. (NASDAQ:PODD) has received an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $253.27.

PODD has been the subject of a number of recent research reports. Sanford C. Bernstein initiated coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective for the company. UBS Group increased their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Barclays increased their price target on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Citigroup increased their price target on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Finally, Canaccord Genuity Group increased their price target on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th.

Hedge Funds Weigh In On Insulet

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. QRG Capital Management Inc. purchased a new position in Insulet in the 3rd quarter valued at approximately $297,000. Diversified Trust Co boosted its position in Insulet by 90.9% in the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after buying an additional 4,348 shares during the period. Linden Thomas Advisory Services LLC boosted its position in Insulet by 65.8% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 8,812 shares of the medical instruments supplier’s stock valued at $1,778,000 after buying an additional 3,497 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Insulet by 38.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier’s stock valued at $36,202,000 after purchasing an additional 50,101 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky raised its holdings in shares of Insulet by 23.9% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 35,035 shares of the medical instruments supplier’s stock valued at $6,006,000 after purchasing an additional 6,754 shares in the last quarter.

Insulet Stock Down 0.1 %

PODD stock opened at $266.42 on Friday. The company has a market cap of $18.69 billion, a price-to-earnings ratio of 45.62, a PEG ratio of 4.02 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet has a 12 month low of $160.19 and a 12 month high of $279.40. The firm has a 50-day moving average of $241.97 and a two-hundred day moving average of $211.65.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.